Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata

Baricitinib, a JAK inhibitor, has been approved by the FDA for treating severe alopecia areata in adults, showing promising results in the BRAVE-AA1 and BRAVE-AA2 trials with over 1300 subjects. These trials demonstrated that Baricitinib is effective and has a favorable safety profile, with the most common side effect being upper respiratory infections. The trials showed that 34% of subjects on a 4-mg dose and 20% on a 2-mg dose experienced significant hair regrowth. While Baricitinib poses some risks, such as herpes zoster reactivation and thromboembolic events, these were less prevalent in AA patients compared to those with rheumatoid arthritis. Physicians should consider patient history, especially cardiovascular conditions, when prescribing Baricitinib. Further studies are needed to assess long-term safety and relapse rates.